Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Phase Study to Evaluate the MEK Inhibitor Selumetinib With the MDM2 Inhibitor APG-115 in Patients With Neurofibromatosis Type 1 and Pre-malignant and Malignant Peripheral Nerve Sheath Tumors

NCT06735820 is registered in ClinicalTrials.gov with AeRang Kim as lead sponsor.

NCT NCT06735820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06735820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Phase Study to Evaluate the MEK Inhibitor Selumetinib With the MDM2 Inhibitor APG-115 in Patients With Neurofibromatosis Type 1 and Pre-malignant and Malignant Peripheral Nerve Sheath Tumors
Lead sponsor
AeRang Kim
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 1, 2026
Completion date
October 1, 2028
Enrollment
45 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

atypical neurofibroma, malignant peripheral nerve sheath tumor (mpnst), neurofibromatosis 1 (nf1)